3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
Home-Grown Partnership Pays Dividends
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
You may also be interested in...
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.
China is signalling its intention to gradually re-open its borders amid real-world data showing few mild-to-moderate cases progress to severe symptoms. Meanwhile, Pfizer's Paxlovid is seemingly struggling to gain traction amid use guideline changes.